Preservation of Fertility or Ovarian Function in Patients with Breast Cancer or Gynecologic and Internal Malignancies

Abstract

Because of the efficacy of systemic therapies, neoplasias which occur in pediatric and adolescent patients and in young adults have high cure rates. This means that fulfilling their wish to have children has become a more pressing concern, particularly among young women with malignant tumors. Premature ovarian failure is also a not insignificant problem as it has a lasting detrimental effect on quality of life. Every oncology patient who may potentially wish to have children should be informed about their options for preserving fertility prior to starting treatment. The rates of patient who received detailed briefing on this point remain low. This review presents the effects of different chemotherapeutic drugs on gonadal function together with an overview of currently valid recommendations on fertility preservation. Risk groups are defined and the specific approaches for malignancies of various organ systems are described. Cryopreservation of oocytes, fertilized embryos and ovarian tissue are fertility-preserving options for girls/young women. The data on the benefits of administering GnRH analogs for ovarian protection prior to starting chemotherapy are not clear. In postpubertal boys or male cancer patients, the standard approach is to cryopreserve sperm before starting therapy. The cryopreservation of testicular tissue is possible for prepubertal boys, however in-vitro sperm maturation is still in its experimental stages. This review also presents existing drug options for the preservation of ovarian function in oncology patients prior to chemotherapy, particularly for patients with (hormone-sensitive) breast cancer, and looks at the special issues of fertility-preserving surgery and radiation therapy in patients with gynecologic malignancies.

Key words

breast cancer - premature ovarian failure - chemotherapy - gynecolocic malignancies - irradiation - infertility

• References/Literatur

• 1 Park WC. Role of ovarian function suppression in premenopausal women with early breast cancer. J Breast Cancer 2016; 19: 341-348
• 2 Munhoz RR, Pereira AA, Sasse AD. et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis. JAMA Oncol 2016; 2: 65-73
• 3 Petrek JA, Naughton MJ, Case LD. et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006; 24: 1045-1051
• 4 Müller H. [Effects of adjuvant chemotherapy of breast cancer on gonadal function]. Zentralbl Gynakol 1990; 112: 795-801
• 5 Overbeek A, van den Berg MH, van Leeuwen FE. et al. Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood and young adult cancer: a systematic review. Cancer Treat Rev 2016; 53: 10-24
• 6 Borgmann-Staudt ABN, Jantke A, Hinz S. AWMF S1-Leitlinie (025/034) Beeinträchtigung der Gonadenfunktion nach Krebs im Kindes- und Jugendalter: Risiken, Diagnostik, Prophylaxe- und Behandlungsmöglichkeiten. AWMF-Register Nr. 025-034. 2015. Online, last access: 03.05.2017
• 7 Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered?. Lancet Oncol 2005; 6: 209-218
• 8 Revelli A, Salvagno F, Delle Piane L. et al. Fertility preservation in BRCA mutation carriers. Minerva Ginecol 2016; 68: 587-601
• 9 Nielsen CT, Skakkebaek NE, Richardson DW. et al. Onset of the release of spermatozoa (spermarche) in boys in relation to age, testicular growth, pubic hair, and height. J Clin Endocrinol Metab 1986; 62: 532-535
• 10 Barton SE, Najita JS, Ginsburg ES. et al. Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol 2013; 14: 873-881
• 11 Metzger ML, Meacham LR, Patterson B. et al. Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications. J Clin Oncol 2013; 31: 1239-1247
• 12 Sklar CA, Mertens AC, Mitby P. et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 2006; 98: 890-896
• 13 Font-Gonzalez A, Mulder RL, Loeffen EA. et al. Fertility preservation in children, adolescents, and young adults with cancer: quality of clinical practice guidelines and variations in recommendations. Cancer 2016; 122: 2216-2223
• 14 Filippi F, Meazza C, Paffoni A. et al. Egg freezing in childhood and young adult cancer survivors. Pediatrics 2016; DOI: 10.1542/peds.2016-0291.
• 15 Long CJ, Ginsberg JP, Kolon TF. Fertility preservation in children and adolescents with cancer. Urology 2016; 91: 190-196
• 16 Salama M, Isachenko V, Isachenko E. et al. Updates in preserving reproductive potential of prepubertal girls with cancer: systematic review. Crit Rev Oncol Hematol 2016; 103: 10-21
• 17 Jensen AK, Rechnitzer C, Macklon KT. et al. Cryopreservation of ovarian tissue for fertility preservation in a large cohort of young girls: focus on pubertal development. Hum Reprod 2017; 32: 154-164
• 18 Trivers KF, Fink AK, Partridge AH. et al. Estimates of young breast cancer survivors at risk for infertility in the U.S. Oncologist 2014; 19: 814-822
• 19 Robert Koch-Institut. Evaluation of cancer incidence in Germany (2007–2010). 2012. Online, last access: 03.05.2017
• 20 Regan MM, Francis PA, Pagani O. et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials. J Clin Oncol 2016; 34: 2221-2231
• 21 Mathew A, Davidson NE. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer. Breast 2015; 24 (Suppl. 02) S120-S125
• 22 Jung M, Shin HJ, Rha SY. et al. The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up. Ann Surg Oncol 2010; 17: 3259-3268
• 23 Zavos A, Valachis A. Risk of chemotherapy-induced amenorrhea in patients with breast cancer: a systematic review and meta-analysis. Acta Oncol 2016; 55: 664-670
• 24 Chai J, Howie AF, Cameron DA. et al. A highly-sensitive anti-Mullerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer. Eur J Cancer 2014; 50: 2367-2374
• 25 Bozza C, Puglisi F, Lambertini M. et al. Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients. Endocr Relat Cancer 2014; 21: R51-R65
• 26 Henry NL, Xia R, Schott AF. et al. Prediction of postchemotherapy ovarian function using markers of ovarian reserve. Oncologist 2014; 19: 68-74
• 27 Anderson RA, Rosendahl M, Kelsey TW. et al. Pretreatment anti-Mullerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur J Cancer 2013; 49: 3404-3411
• 28 Khairy M, Clough A, El-Toukhy T. et al. Antral follicle count at down-regulation and prediction of poor ovarian response. Reprod Biomed Online 2008; 17: 508-514
• 29 Okanami Y, Ito Y, Watanabe C. et al. Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane. Breast Cancer 2011; 18: 182-188
• 30 Pourali L, Taghizadeh Kermani A, Ghavamnasiri MR. et al. Incidence of chemotherapy-induced amenorrhea after adjuvant chemotherapy with taxane and anthracyclines in young patients with breast cancer. Iran J Cancer Prev 2013; 6: 147-150
• 31 Chapman C, Cree L, Shelling AN. The genetics of premature ovarian failure: current perspectives. Int J Womens Health 2015; 7: 799-810
• 32 Reimer T, Kempert S, Gerber B. et al. SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study. BMC Cancer 2016; 16: 337
• 33 Stearns V, Schneider B, Henry NL. et al. Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. Nat Rev Cancer 2006; 6: 886-893
• 34 Cardoso F, vanʼt Veer LJ, Bogaerts J. et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 2016; 375: 717-729
• 35 Nitz U, Gluz O, Christgen M. et al. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. Breast Cancer Res Treat 2017; DOI: 10.1007/s10549-017-4358-6.
• 36 Duffy MJ, Harbeck N, Nap M. et al. Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer 2017; 75: 284-298
• 37 Morgan S, Anderson RA, Gourley C. et al. How do chemotherapeutic agents damage the ovary?. Hum Reprod Update 2012; 18: 525-535
• 38 Moore HC, Unger JM, Phillips KA. et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015; 372: 923-932
• 39 Gerber B, Ortmann O. Prevention of Early Menopause Study (POEMS): is it possible to preserve ovarian function by gonadotropin releasing hormone analogs (GnRHa)?. Arch Gynecol Obstet 2014; 290: 1051-1053
• 40 Lambertini M, Ceppi M, Poggio F. et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol 2015; 26: 2408-2419
• 41 Lambertini M, Cinquini M, Moschetti I. et al. Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. Eur J Cancer 2017; 71: 25-33
• 42 Badawy A, Elnashar A, El Ashry M. et al. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009; 91: 694-697
• 43 Sverrisdottir A, Nystedt M, Johansson H. et al. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 2009; 117: 561-567
• 44 Del Mastro L, Boni L, Michelotti A. et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011; 306: 269-276
• 45 Gerber B, von Minckwitz G, Stehle H. et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 2011; 29: 2334-2341
• 46 Munster PN, Moore AP, Ismail-Khan R. et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 2012; 30: 533-538
• 47 Elgindy EA, El Haieg DO, Khorshid OM. et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol 2013; 121: 78-86
• 48 Ronn R, Holzer H. Breast cancer and fertility: an update. Curr Opin Support Palliat Care 2015; 9: 285-293
• 49 Loren AW, Mangu PB, Beck LN. et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31: 2500-2510
• 50 Rodriguez-Wallberg KA, Tanbo T, Tinkanen H. et al. Ovarian tissue cryopreservation and transplantation among alternatives for fertility preservation in the Nordic countries – compilation of 20 years of multicenter experience. Acta Obstet Gynecol Scand 2016; 95: 1015-1026
• 51 Shapira M, Raanani H, Meirow D. IVF for fertility preservation in breast cancer patients–efficacy and safety issues. J Assist Reprod Genet 2015; 32: 1171-1178
• 52 Van der Ven H, Liebenthron J, Beckmann M. et al. Ninety-five orthotopic transplantations in 74 women of ovarian tissue after cytotoxic treatment in a fertility preservation network: tissue activity, pregnancy and delivery rates. Hum Reprod 2016; 31: 2031-2041
• 53 Beckmann MW, Dittrich R, Lotz L. et al. Operative techniques and complications of extraction and transplantation of ovarian tissue: the Erlangen experience. Arch Gynecol Obstet 2017; 295: 1033-1039
• 54 Beckmann MW, Dittrich R, Findeklee S. et al. Surgical aspects of ovarian tissue removal and ovarian tissue transplantation for fertility preservation. Geburtsh Frauenheilk 2016; 76: 1057-1064
• 55 Findeklee S, Lotz L, Heusinger K. et al. Fertility protection in female oncology patients: how should patients be counseled?. Geburtsh Frauenheilk 2015; 75: 1243-1249
• 56 Rosendahl M, Andersen MT, Ralfkiaer E. et al. Evidence of residual disease in cryopreserved ovarian cortex from female patients with leukemia. Fertil Steril 2010; 94: 2186-2190
• 57 du Bois A, Trillsch F, Mahner S. et al. Management of borderline ovarian tumors. Ann Oncol 2016; 27 (Suppl. 01) i20-i22
• 58 Gershenson DM. Management of borderline ovarian tumours. Best Pract Res Clin Obstet Gynaecol 2016; DOI: 10.1016/j.bpobgyn.2016.09.012.
• 59 Karlsen NM, Karlsen MA, Hogdall E. et al. Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT). Gynecol Oncol 2016; 142: 50-53
• 60 Zapardiel I, Diestro MD, Aletti G. Conservative treatment of early stage ovarian cancer: oncological and fertility outcomes. Eur J Surg Oncol 2014; 40: 387-393
• 61 Demirkiran F, Sal V, Bese T. et al. Risk factors for recurrence of borderline ovarian tumours: a tertiary centre experience. J Obstet Gynaecol 2016; 36: 1036-1040
• 62 Bentivegna E, Fruscio R, Roussin S. et al. Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: review of the results of an international multicenter study comprising 545 patients. Fertil Steril 2015; 104: 1319-1324
• 63 Park JY, Suh DS, Kim JH. et al. Outcomes of fertility-sparing surgery among young women with FIGO stage I clear cell carcinoma of the ovary. Int J Gynaecol Obstet 2016; 134: 49-52
• 64 Ghezzi F, Cromi A, Fanfani F. et al. Laparoscopic fertility-sparing surgery for early ovarian epithelial cancer: a multi-institutional experience. Gynecol Oncol 2016; 141: 461-465
• 65 Parkinson CA, Hatcher HM, Ajithkumar TV. Management of malignant ovarian germ cell tumors. Obstet Gynecol Surv 2011; 66: 507-514
• 66 Iavazzo C, Gkegkes ID, Vrachnis N. Fertility sparing management and pregnancy in patients with granulosa cell tumour of the ovaries. J Obstet Gynaecol 2015; 35: 331-335
• 67 Zapardiel I, Cruz M, Diestro MD. et al. Assisted reproductive techniques after fertility-sparing treatments in gynaecological cancers. Hum Reprod Update 2016; DOI: 10.1093/humupd/dmv066.
• 68 Lian C, Chen X, Ni Y. et al. Pregnancy after fertility-sparing surgery for borderline ovarian tumors. Int J Gynaecol Obstet 2016; 134: 282-285
• 69 Dargent D, Martin X, Sacchetoni A. et al. Laparoscopic vaginal radical trachelectomy: a treatment to preserve the fertility of cervical carcinoma patients. Cancer 2000; 88: 1877-1882
• 70 Hertel H, Kohler C, Grund D. et al. Radical vaginal trachelectomy (RVT) combined with laparoscopic pelvic lymphadenectomy: prospective multicenter study of 100 patients with early cervical cancer. Gynecol Oncol 2006; 103: 506-511
• 71 Shepherd JH, Spencer C, Herod J. et al. Radical vaginal trachelectomy as a fertility-sparing procedure in women with early-stage cervical cancer-cumulative pregnancy rate in a series of 123 women. BJOG 2006; 113: 719-724
• 72 Hoeckel M. Die Post-Wertheim-Emanzipation und -Evolution der operativen Therapie des Zervixkarzinoms. Geburtsh Frauenheilk 2006; 66: 729-733
• 73 Willows K, Lennox G, Covens A. Fertility-sparing management in cervical cancer: balancing oncologic outcomes with reproductive success. Gynecol Oncol Res Pract 2016; 3: 9
• 74 Hauerberg L, Hogdall C, Loft A. et al. Vaginal radical trachelectomy for early stage cervical cancer. Results of the Danish National Single Center Strategy. Gynecol Oncol 2015; 138: 304-310
• 75 Pareja R, Rendon GJ, Sanz-Lomana CM. et al. Surgical, oncological, and obstetrical outcomes after abdominal radical trachelectomy – a systematic literature review. Gynecol Oncol 2013; 131: 77-82
• 76 Zusterzeel PL, Pol FJ, van Ham M. et al. Vaginal radical trachelectomy for early-stage cervical cancer: increased recurrence risk for adenocarcinoma. Int J Gynecol Cancer 2016; 26: 1293-1299
• 77 Reimer T, Stachs A, Günzl N. et al. Die radikale abdominale Trachelektomie: Zwei Kasuistiken zum fertilitätserhaltenden Vorgehen beim frühinvasiven Zervixkarzinom. Geburtsh Frauenheilk 2009; 69: 240-243
• 78 Bentivegna E, Gouy S, Maulard A. et al. Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review. Lancet Oncol 2016; 17: e240-e253
• 79 Mangler M, Lanowska M, Bartens A. et al. Closure of the cervical os in patients after fertility preserving treatment for early cervical cancer – results of a prospective observational study. J Perinat Med 2016; DOI: 10.1515/jpm-2016-0231.
• 80 Boss EA, van Golde RJ, Beerendonk CC. et al. Pregnancy after radical trachelectomy: a real option?. Gynecol Oncol 2005; 99: S152-S156
• 81 Chemaitilly W, Mertens AC, Mitby P. et al. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab 2006; 91: 1723-1728
• 82 Cholakian D, Hacker K, Fader AN. et al. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer. Gynecol Oncol 2016; 140: 234-238
• 83 Wang CJ, Chao A, Yang LY. et al. Fertility-preserving treatment in young women with endometrial adenocarcinoma: a long-term cohort study. Int J Gynecol Cancer 2014; 24: 718-728
• 84 Falcone F, Laurelli G, Losito S. et al. Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer. J Gynecol Oncol 2017; 28: e2